VACCINE COMPOSITIONS BASED ON STICHOLYSIN ENCAPSULATED INTO LIPOSOMES

CLAIMS:

1. - A vaccinal vehicle to induce cell immune response comprising co-encapsulation into liposomal vesicles of proteins obtained from the anemone *Stichodactyla helianthus* and an antigen.

2. - The vaccinal vehicle according to claim 1 wherein the lipid vesicle contains DPPC and Cho in an equimolar ratio.

3. - The vaccinal vehicle according to claim 1 wherein the proteins from the anemone *Stichodactyla helianthus* are selected from the group comprising StII, StI and their variants.

4. - The vaccinal vehicle according to claim 3 wherein the variants of St toxins are selected from the group comprising StIW111C, StIW111Cirrev or heat-inactivated StII.

5.- The vaccinal vehicle according to claim 1 wherein the antigen is a protein or a polypeptide associated to a pathology selected from the group comprising cancer and infectious diseased caused by intracellular pathogens.

6. - The vaccinal vehicle according to claim 5 wherein the antigen is a protein or a polypeptide associated with cancer.

7. - The vaccinal vehicle according to claim 5 wherein the antigen is a protein or a polypeptide associated with AIDS.

8. - The vaccinal vehicle according to claim 5 wherein the antigen is a protein or a polypeptide associated with tuberculosis.

9. - A vaccinal composition comprising any of the vaccinal vehicle according to claims 1 - 9 and lacking immunological adjuvants.

10.- The use of the vaccinal composition according to claim 9 useful for enhancing the immune response of a patient suffering from a disease selected from the group comprising cancer and infectious diseases caused by intracellular pathogens.

Claims:

1. A vaccine composition comprising an antigen and proteins obtained from *Stichodactyla helianthus* selected from the group consisting of Sticholysin I (StI), Sticholysin II (StII), Sticholysin I mutant W111C (StIW111C), StIW1111C irreversibly inactivated dimer (StIW111Cirrev) and heat-inactivated StII, wherein the antigen and the proteins are encapsulated in a liposomal vesicle that contains dipalmitoylphosphatidylcholine (DPPC) and cholesterol (Cho) in an equimolar ratio.

2. The vaccine composition of claim 12, wherein the antigen is a protein or a polypeptide which induces a specific cytotoxic T lymphocyte immune response against cancer.

3. The vaccine composition of claim 12, wherein said vaccine composition does not contain any other immunological adjuvants.